SI1054887T1 - Biciklicni pridinski in primidinski derivati kot receptorski antagonisti nevropeptida y - Google Patents
Biciklicni pridinski in primidinski derivati kot receptorski antagonisti nevropeptida yInfo
- Publication number
- SI1054887T1 SI1054887T1 SI9930893T SI9930893T SI1054887T1 SI 1054887 T1 SI1054887 T1 SI 1054887T1 SI 9930893 T SI9930893 T SI 9930893T SI 9930893 T SI9930893 T SI 9930893T SI 1054887 T1 SI1054887 T1 SI 1054887T1
- Authority
- SI
- Slovenia
- Prior art keywords
- neuropeptide
- receptor antagonists
- pyrimidine derivatives
- bicyclic pyridine
- bicyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7392798P | 1998-02-06 | 1998-02-06 | |
US7398198P | 1998-02-06 | 1998-02-06 | |
US9348298P | 1998-07-20 | 1998-07-20 | |
US9357798P | 1998-07-20 | 1998-07-20 | |
US09/246,775 US6187777B1 (en) | 1998-02-06 | 1999-02-04 | Compounds and methods which modulate feeding behavior and related diseases |
PCT/US1999/002500 WO1999040091A1 (en) | 1998-02-06 | 1999-02-05 | Bicyclic pyridine and pyrimidine derivatives as neuropeptide y receptor antagonists |
EP99906756A EP1054887B1 (en) | 1998-02-06 | 1999-02-05 | Bicyclic pyridine and pyrimidine derivatives as neuropeptide y receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
SI1054887T1 true SI1054887T1 (sl) | 2006-08-31 |
Family
ID=27535987
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI9930893T SI1054887T1 (sl) | 1998-02-06 | 1999-02-05 | Biciklicni pridinski in primidinski derivati kot receptorski antagonisti nevropeptida y |
Country Status (13)
Country | Link |
---|---|
US (2) | US6187777B1 (sl) |
EP (1) | EP1054887B1 (sl) |
JP (1) | JP2003502272A (sl) |
AT (1) | ATE323088T1 (sl) |
AU (1) | AU747920B2 (sl) |
CA (1) | CA2319275C (sl) |
CY (1) | CY1105476T1 (sl) |
DE (1) | DE69930835T2 (sl) |
DK (1) | DK1054887T3 (sl) |
ES (1) | ES2257851T3 (sl) |
PT (1) | PT1054887E (sl) |
SI (1) | SI1054887T1 (sl) |
WO (1) | WO1999040091A1 (sl) |
Families Citing this family (126)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69638122D1 (de) * | 1996-09-04 | 2010-03-18 | Intertrust Tech Corp | Zuverlässige Infrastrukturhilfssysteme, Verfahren und Techniken für sicheren elektronischen Handel, elektronische Transaktionen, Handelsablaufsteuerung und Automatisierung, verteilte Verarbeitung und Rechteverwaltung |
ES2247676T3 (es) * | 1997-01-07 | 2006-03-01 | Amylin Pharmaceuticals, Inc. | Uso de las exendinas y de los agonistas de las mismas para la reduccion de la ingesta alimenticia. |
CN101328186A (zh) | 1997-11-11 | 2008-12-24 | 辉瑞产品公司 | 用作抗癌药的噻吩并嘧啶和噻吩并吡啶衍生物 |
AU756797B2 (en) | 1998-11-10 | 2003-01-23 | Banyu Pharmaceutical Co., Ltd. | Spiro-indolines as Y5 receptor antagonists |
EP1129091B1 (en) | 1998-11-12 | 2002-10-02 | Neurocrine Biosciences, Inc. | Crf receptor antagonists and methods relating thereto |
US6531475B1 (en) * | 1998-11-12 | 2003-03-11 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods relating thereto |
CA2634299C (en) * | 1999-04-08 | 2011-05-31 | Industrial Research Limited | Process for preparing inhibitors of nucleoside metabolism |
GB9915437D0 (en) | 1999-07-01 | 1999-09-01 | Cerebrus Ltd | Chemical compounds III |
CA2383524C (en) * | 1999-08-31 | 2010-09-28 | Merck & Co., Inc. | Thiazolyl alkynyl compounds and methods of use thereof |
EA200200424A1 (ru) | 1999-09-30 | 2002-12-26 | Ньюроджен Корпорейшн | Некоторые гетероциклы, замещенные алкилендиамином |
AU7737900A (en) * | 1999-09-30 | 2001-04-30 | Neurogen Corporation | Amino substituted pyrazolo(1,5,-a)-1,5-pyrimidines and pyrazolo(1,5-a)-1,3,5-triazines |
YU23802A (sh) * | 1999-09-30 | 2004-09-03 | Neurogen Corporation | Određeni alkilen diamin-supstituisani pirazolo/1,5-a/-1,5- piramidini i pirazolo/1,5-a/1,3,5-triazini |
US6440960B1 (en) | 2000-05-18 | 2002-08-27 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods relating thereto |
US7276492B2 (en) * | 2000-06-01 | 2007-10-02 | Kevorkian Robert C | Use of ACE inhibitors for treatment of patients suffering from behavioral disorders |
JP2004510736A (ja) * | 2000-10-03 | 2004-04-08 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | アルコール中毒治療における神経ペプチドy拮抗物質の使用 |
US8564661B2 (en) | 2000-10-24 | 2013-10-22 | Objectvideo, Inc. | Video analytic rule detection system and method |
GB0100620D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical cokpounds V |
US20050226918A1 (en) * | 2001-08-13 | 2005-10-13 | Macdonald Stuart G | Delivery system for insulin and other therapeutic agents |
US6770652B2 (en) * | 2001-10-18 | 2004-08-03 | Duquesne University Of The Holy Ghost | Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same |
ES2193875B2 (es) | 2002-04-09 | 2005-03-01 | Laboratorios Del Dr. Esteve, S.A. | Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos. |
AR039385A1 (es) | 2002-04-19 | 2005-02-16 | Astrazeneca Ab | Derivados de tioxantina como inhibidores de la mieloperoxidasa |
TW200403243A (en) | 2002-07-18 | 2004-03-01 | Wyeth Corp | 1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
DK1599468T3 (da) * | 2003-01-14 | 2008-02-04 | Arena Pharm Inc | 1,2,3-trisubstituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser forbundet dermed såsom diabetes og hyperglykæmi |
CN1835943B (zh) * | 2003-01-14 | 2012-03-07 | 阿伦纳药品公司 | 作为代谢调节剂的1,2,3-三取代的芳基和杂芳基衍生物及其应用 |
EP1927594A1 (en) | 2003-01-14 | 2008-06-04 | Arena Pharmaceuticals, Inc. | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
CN1751038A (zh) * | 2003-02-24 | 2006-03-22 | 艾尼纳制药公司 | 作为葡萄糖代谢调节剂的经取代芳基和杂芳基衍生物及葡萄糖代谢失调的预防和治疗 |
EP2028180A1 (en) * | 2003-03-04 | 2009-02-25 | ADDEX Pharma S.A. | Novel aminopyridine derivatives as mGluR5 antagonists |
US7834014B2 (en) | 2003-04-09 | 2010-11-16 | Biogen Idec Ma Inc. | A2a adenosine receptor antagonists |
EP1615931A1 (en) | 2003-04-09 | 2006-01-18 | Biogen Idec MA Inc. | Triazolopyrazines and methods of making and using the same |
WO2004092170A2 (en) | 2003-04-09 | 2004-10-28 | Biogen Idec Ma Inc. | Triazolotriazines and pyrazolotriazines useful as a2a adenosine receptor antagon ists |
US7616233B2 (en) * | 2003-06-26 | 2009-11-10 | Fotonation Vision Limited | Perfecting of digital image capture parameters within acquisition devices using face detection |
ATE365167T1 (de) * | 2003-07-10 | 2007-07-15 | Neurogen Corp | Aryl-substituierte benzo(d)isothiazol-3-ylamin analoga als capsaicinrezeptormodulatoren |
AR045047A1 (es) * | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
ES2222833B1 (es) | 2003-07-30 | 2006-03-01 | Laboratorios Del Dr. Esteve, S.A. | Compuestos piperidinicos 1,4-disustituidos, su preparacion y su uso como medicamentos. |
MEP8409A (en) * | 2004-06-02 | 2011-12-20 | Fused heterocyclic compound | |
CN1993362B (zh) * | 2004-06-02 | 2010-12-15 | 武田药品工业株式会社 | 稠合的杂环化合物 |
DK1756084T3 (da) * | 2004-06-04 | 2009-03-23 | Arena Pharm Inc | Substituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser beslægtet dermed |
US7601725B2 (en) * | 2004-07-16 | 2009-10-13 | Sunesis Pharmaceuticals, Inc. | Thienopyrimidines useful as Aurora kinase inhibitors |
GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
US7674822B2 (en) | 2004-11-24 | 2010-03-09 | Wyeth | PTP1b inhibitors |
MY140748A (en) * | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
FR2878849B1 (fr) | 2004-12-06 | 2008-09-12 | Aventis Pharma Sa | Indoles substitues, compositions les contenant, procede de fabrication et utilisation |
DOP2006000010A (es) | 2005-01-10 | 2006-07-31 | Arena Pharm Inc | Procedimiento para preparar eteres aromáticos |
MY148521A (en) * | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
US20070155738A1 (en) * | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
JP5463034B2 (ja) * | 2005-05-20 | 2014-04-09 | アラントス・フアーマシユーテイカルズ・ホールデイング・インコーポレイテツド | ピリミジン若しくはトリアジン縮合二環式メタロプロテアーゼ阻害薬 |
KR101142363B1 (ko) * | 2005-06-27 | 2012-05-21 | 주식회사유한양행 | 피롤로피리딘 유도체를 포함하는 항암제 조성물 |
CN101263135A (zh) * | 2005-09-16 | 2008-09-10 | 艾尼纳制药公司 | 代谢调节剂和代谢相关病症的治疗 |
UY29825A1 (es) * | 2005-10-03 | 2007-05-31 | Astrazeneca Ab | Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones |
AR057525A1 (es) * | 2005-10-03 | 2007-12-05 | Astrazeneca Ab | Compuestos inhibidores selectivos de gsk3 y un proceso para su preparacion |
JPWO2007069565A1 (ja) | 2005-12-12 | 2009-05-21 | 小野薬品工業株式会社 | 二環式複素環化合物 |
GB0608820D0 (en) * | 2006-05-04 | 2006-06-14 | Piramed Ltd | Pharmaceutical compounds |
TW200804383A (en) | 2006-06-05 | 2008-01-16 | Astrazeneca Ab | New compounds |
TW200811147A (en) * | 2006-07-06 | 2008-03-01 | Arena Pharm Inc | Modulators of metabolism and the treatment of disorders related thereto |
TW200811140A (en) * | 2006-07-06 | 2008-03-01 | Arena Pharm Inc | Modulators of metabolism and the treatment of disorders related thereto |
ATE512969T1 (de) | 2006-09-21 | 2011-07-15 | Raqualia Pharma Inc | Benzimidazolderivate als selektive säurepumpenhemmer |
KR101507182B1 (ko) * | 2006-12-07 | 2015-03-30 | 제넨테크, 인크. | 포스포이노시타이드 3-키나제 억제제 화합물 및 그의 사용 방법 |
KR101460816B1 (ko) | 2006-12-07 | 2014-11-12 | 에프. 호프만-라 로슈 아게 | 포스포이노시타이드 3-키나제 억제제 화합물 및 그의 사용 방법 |
WO2008082839A2 (en) * | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Pim kinase inhibitors as cancer chemotherapeutics |
ES2399774T3 (es) | 2007-09-24 | 2013-04-03 | Genentech, Inc. | Compuestos de tiazolopirimidina inhibidores de PI3K y métodos de uso |
US8354528B2 (en) | 2007-10-25 | 2013-01-15 | Genentech, Inc. | Process for making thienopyrimidine compounds |
CA2703600C (en) * | 2007-11-15 | 2017-04-25 | Ym Biosciences Australia Pty Ltd | Fused thieno or pyrrolo pyrimidine heterocyclic compounds and use thereof as jak1, jak2, and/or jak3 inhibitors |
AR070454A1 (es) * | 2008-02-27 | 2010-04-07 | Nycomed Gmbh | Pirrolopirimidincarboxamidas y composiciones farmaceuticas que las comprenden |
KR20110046514A (ko) * | 2008-07-31 | 2011-05-04 | 제넨테크, 인크. | 피리미딘 화합물, 조성물 및 사용 방법 |
UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
DE102008052943A1 (de) * | 2008-10-23 | 2010-04-29 | Merck Patent Gmbh | Azaindolderivate |
JP5709766B2 (ja) | 2009-03-12 | 2015-04-30 | ジェネンテック, インコーポレイテッド | 造血器腫瘍の治療のためのホスホイノシチド3キナーゼ阻害剤化合物と化学療法剤の併用 |
US8158625B2 (en) * | 2009-05-27 | 2012-04-17 | Genentech, Inc. | Bicyclic indole-pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use |
CA2761445A1 (en) | 2009-05-27 | 2010-12-02 | Genentech, Inc. | Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
US20100331305A1 (en) * | 2009-06-24 | 2010-12-30 | Genentech, Inc. | Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use |
AR077898A1 (es) * | 2009-08-26 | 2011-09-28 | Nycomed Gmbh | Metilpirrolopirimidincarboxamidas |
CN102711766B (zh) * | 2009-11-12 | 2014-06-04 | 霍夫曼-拉罗奇有限公司 | N-9-取代的嘌呤化合物、组合物和使用方法 |
JP5572715B2 (ja) * | 2009-11-12 | 2014-08-13 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | N−7置換プリン及びピラゾロピリミジン化合物、組成物及び使用方法 |
ES2937386T3 (es) | 2010-01-27 | 2023-03-28 | Arena Pharm Inc | Procesos para la preparación de ácido (R)-2-(7-(4-ciclopentil-3-(trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3-il)acético y sales del mismo |
MX2012011887A (es) | 2010-04-16 | 2012-11-30 | Genentech Inc | Foxo 3a como biomarcador predictivo para la eficacia del inhibidor de la via de quinasa pi3k/akt. |
KR20130108318A (ko) | 2010-08-27 | 2013-10-02 | 메르크 파텐트 게엠베하 | 푸로피리딘 유도체들 |
SG188548A1 (en) | 2010-09-22 | 2013-04-30 | Arena Pharm Inc | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
US20140004209A1 (en) | 2010-12-22 | 2014-01-02 | Genentech, Inc. | Autophagy inducer and inhibitor combination therapy for the treatment of neoplasms |
EP2694484B1 (en) | 2011-04-08 | 2018-07-18 | Janssen Sciences Ireland UC | Pyrimidine derivatives for the treatment of viral infections |
PL2734186T3 (pl) | 2011-07-22 | 2019-01-31 | Glaxosmithkline Llc | Kompozycja |
DE102011111400A1 (de) | 2011-08-23 | 2013-02-28 | Merck Patent Gmbh | Bicyclische heteroaromatische Verbindungen |
BR112014011162A2 (pt) | 2011-11-09 | 2017-05-09 | Janssen R&D Ireland | derivados purínicos para o tratamento de infecções virais |
AU2012340869B2 (en) | 2011-11-23 | 2017-03-02 | Cancer Research Technology Limited | Thienopyrimidine inhibitors of atypical protein kinase C |
SI2812337T1 (sl) * | 2012-02-09 | 2017-01-31 | Merck Patent Gmbh | Furo (3,2-b) in tieno (3,2-b) piridinski derivati kot zaviralci tbk1 in ikk |
WO2013124025A1 (en) * | 2012-02-21 | 2013-08-29 | Merck Patent Gmbh | Furopyridine derivatives |
TW201414734A (zh) | 2012-07-10 | 2014-04-16 | Takeda Pharmaceutical | 氮雜吲哚衍生物 |
EA035790B1 (ru) | 2012-07-13 | 2020-08-11 | Янссен Сайенсиз Айрлэнд Юси | Макроциклические пурины для лечения вирусных инфекций |
SG11201500787YA (en) | 2012-08-24 | 2015-03-30 | Glaxosmithkline Llc | Pyrazolopyrimidine compounds |
HUE037064T2 (hu) | 2012-10-10 | 2018-08-28 | Janssen Sciences Ireland Uc | Pirrolo[3,2-d]-pirimidin származékok vírusos fertõzések és egyéb betegségek kezelésére |
US9663474B2 (en) | 2012-11-16 | 2017-05-30 | Janssen Sciences Ireland Uc | Heterocyclic substituted 2-amino quinazoline derivatives for the treatment of viral infections |
ES2625023T3 (es) | 2012-11-20 | 2017-07-18 | Glaxosmithkline Llc | Compuestos novedosos |
JP6228223B2 (ja) | 2012-11-20 | 2017-11-08 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC | 新規化合物 |
US9550785B2 (en) | 2012-11-20 | 2017-01-24 | Glaxosmithkline Llc | Pyrrolopyrimidines as therapeutic agents for the treatment of diseases |
WO2014100071A2 (en) * | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted pyrrolopyrimidines as hdm2 inhibitors |
ES2733361T3 (es) | 2013-02-21 | 2019-11-28 | Janssen Sciences Ireland Unlimited Co | Derivados de 2-aminopirimidina para el tratamiento de infecciones víricas |
JP6669500B2 (ja) | 2013-02-25 | 2020-03-18 | ジェネンテック, インコーポレイテッド | 薬物耐性akt変異体を検出し治療するための方法及び組成物 |
HUE031908T2 (en) | 2013-03-29 | 2017-08-28 | Janssen Sciences Ireland Uc | Macrocyclic deaza-purinones for the treatment of viral infections |
CN105377833B (zh) | 2013-05-24 | 2018-11-06 | 爱尔兰詹森科学公司 | 用于治疗病毒感染和另外的疾病的吡啶酮衍生物 |
WO2014207082A1 (en) | 2013-06-27 | 2014-12-31 | Janssen R&D Ireland | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases |
KR102322425B1 (ko) | 2013-07-30 | 2021-11-05 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 바이러스 감염의 치료를 위한 티에노[3,2-d]피리미딘 유도체 |
AR099052A1 (es) | 2014-01-09 | 2016-06-29 | Takeda Pharmaceuticals Co | Derivados de azaindol |
CZ2014295A3 (cs) * | 2014-04-30 | 2015-10-14 | Masarykova Univerzita | Substituované furo[3,2-b]pyridiny pro použití jako léčiva |
EP2940022B1 (en) * | 2014-04-30 | 2020-09-02 | Masarykova Univerzita | Furopyridines as inhibitors of protein kinases |
GB201411236D0 (en) * | 2014-06-25 | 2014-08-06 | Takeda Pharmaceutical | Novel compounds |
CN107454899B (zh) | 2014-10-27 | 2020-05-29 | 大学健康网络 | Ripk2抑制剂及用其治疗癌症的方法 |
EP3242666A1 (en) | 2015-01-06 | 2017-11-15 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
JP6513213B2 (ja) | 2015-03-15 | 2019-05-15 | セイケム インコーポレイテッド | ゼオライトの合成を改善するための構造指向剤 |
JP6838744B2 (ja) | 2015-06-22 | 2021-03-03 | アリーナ ファーマシューティカルズ, インコーポレイテッド | S1P1レセプター関連障害における使用のための(R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸(化合物1)の結晶性L−アルギニン塩 |
CA3008171A1 (en) | 2015-12-22 | 2017-06-29 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
AU2017289418B2 (en) | 2016-07-01 | 2021-06-03 | Janssen Sciences Ireland Unlimited Company | Dihydropyranopyrimidines for the treatment of viral infections |
EP3519406B1 (en) | 2016-09-29 | 2022-02-23 | Janssen Sciences Ireland Unlimited Company | Pyrimidine prodrugs for the treatment of viral infections and further diseases |
KR20190116416A (ko) | 2017-02-16 | 2019-10-14 | 아레나 파마슈티칼스, 인크. | 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법 |
IL310023A (en) | 2017-06-21 | 2024-03-01 | SHY Therapeutics LLC | Compounds interacting with the RAS superfamily for the treatment of cancer, inflammation, RAS pathology and fibrotic diseases |
JOP20180094A1 (ar) | 2017-10-18 | 2019-04-18 | Hk Inno N Corp | مركب حلقي غير متجانس كمثبط بروتين كيناز |
KR20200086709A (ko) | 2017-11-14 | 2020-07-17 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 인돌 화합물 |
BR112020011979A2 (pt) | 2017-12-19 | 2020-11-17 | Bristol-Myers Squibb Company | compostos de indol substituídos por amida úteis como inibidores de tlr |
EP3728253B1 (en) | 2017-12-19 | 2024-03-27 | Bristol-Myers Squibb Company | 6-azaindole compounds |
AU2018390820A1 (en) | 2017-12-19 | 2020-08-06 | Bristol-Myers Squibb Company | Substituted indole compounds useful as TLR inhibitors |
CA3085942A1 (en) | 2017-12-20 | 2019-06-27 | Bristol-Myers Squibb Company | Aryl and heteroaryl substituted indole compounds |
ES2904676T3 (es) | 2017-12-20 | 2022-04-05 | Bristol Myers Squibb Co | Compuestos de amino indol útiles como inhibidores de TLR |
CA3085937A1 (en) * | 2017-12-20 | 2019-06-27 | Bristol-Myers Squibb Company | Diazaindole compounds |
TW201945003A (zh) | 2018-03-01 | 2019-12-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | 2,4-二胺基喹唑啉衍生物及其醫學用途 |
WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
WO2020118183A1 (en) * | 2018-12-06 | 2020-06-11 | Kapoor Tarun M | 2,4-diaminopyrimidine bicycles for treating cancer |
CN114829362A (zh) * | 2019-12-10 | 2022-07-29 | 成都倍特药业股份有限公司 | 一种可用作shp2抑制剂的含氮杂原子的六元并五元芳环衍生物 |
WO2024017227A1 (zh) * | 2022-07-21 | 2024-01-25 | 长春金赛药业有限责任公司 | 取代的稠环***素受体化合物及其应用 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA907618A (en) | 1972-08-15 | Woitun Eberhard | 2-aminoalkylamino-thieno(3,2-d)pyrimidines and process for their production | |
BE754606A (fr) | 1969-08-08 | 1971-02-08 | Thomae Gmbh Dr K | Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication |
US3883651A (en) | 1969-08-08 | 1975-05-13 | Boehringer Sohn Ingelheim | Pharmaceutical compositions containing a 2-(aminoalkylamino)-4-amino-thieno{8 3,2-d{9 pyrimidine and method of use |
BE759493A (fr) | 1969-11-26 | 1971-05-25 | Thomae Gmbh Dr K | Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer |
US3763156A (en) | 1970-01-28 | 1973-10-02 | Boehringer Sohn Ingelheim | 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines |
RO62428A (fr) | 1971-05-04 | 1978-01-15 | Thomae Gmbh Dr K | Procede pour la preparation des thyeno-(3,2-d)-pyrimidines |
PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
US4731368A (en) | 1986-12-08 | 1988-03-15 | Merck & Co., Inc. | Thienopyridine sulfonamides and their ophthalmological formulation |
US4808595A (en) | 1986-12-24 | 1989-02-28 | Merck & Co., Inc. | Furopyridine sulfonamides and their opthalmological compositions |
JPH0527391A (ja) | 1991-07-23 | 1993-02-05 | Konica Corp | 新規な写真用カプラー |
FR2687402B1 (fr) | 1992-02-14 | 1995-06-30 | Lipha | Nouveaux azaindoles, procedes de preparation et medicaments les contenant. |
DK0674641T3 (da) | 1992-12-17 | 1999-09-27 | Pfizer | Pyrrolopyrimidiner som CRF-antagonister |
RU2153494C2 (ru) | 1993-10-12 | 2000-07-27 | Дзе Дюпон Мерк Фармасьютикал Компани | 1-n-алкил-n-арилпиримидинамины, способ лечения заболеваний, фармацевтическая композиция |
US5461065A (en) | 1993-10-15 | 1995-10-24 | Eli Lilly And Company | Methods for inhibiting endometriosis |
US5441965A (en) | 1993-12-21 | 1995-08-15 | Eli Lilly And Company | Methods of inhibiting thrombin |
US5439923A (en) | 1993-12-21 | 1995-08-08 | Eli Lilly And Company | Method of inhibiting seborrhea and acne |
DK0682027T3 (da) | 1994-05-03 | 1998-05-04 | Ciba Geigy Ag | Pyrrolopyrimidinderivater med antiproliferativ virkning |
TW530047B (en) | 1994-06-08 | 2003-05-01 | Pfizer | Corticotropin releasing factor antagonists |
EP0763035A4 (en) | 1994-06-09 | 1997-10-01 | Smithkline Beecham Corp | ENDOTHELIN RECEPTOR ANTAGONISTS |
CN1056611C (zh) | 1994-06-16 | 2000-09-20 | 美国辉瑞有限公司 | 吡唑并吡啶和吡咯并吡啶,其用途和用于制备它们的中间体 |
US6562862B1 (en) | 1994-10-20 | 2003-05-13 | Eli Lilly And Company | Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y |
IL115613A0 (en) | 1994-10-20 | 1996-01-19 | Lilly Co Eli | Bicyclic neuropeptide y receptor antagonists |
KR970707101A (ko) | 1994-11-07 | 1997-12-01 | 스피겔 알렌 제이 | 치환된 벤질아민 유도체; 신규한 부류의 신경펩타이드 y1 특이적 리간드(certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands) |
EP0729758A3 (en) | 1995-03-02 | 1997-10-29 | Pfizer | Pyrazolopyrimidines and pyrrolopyrimidines to treat neuronal disorders and other diseases |
AU716993B2 (en) | 1995-05-12 | 2000-03-16 | Neurogen Corporation | Novel deazapurine derivatives; a new class of CRF1 specific ligands |
US5644057A (en) * | 1995-05-12 | 1997-07-01 | Neurogen Corporation | Deazapurine derivatives; a new class of CRF1 specific ligands |
MX9709867A (es) | 1995-06-07 | 1998-03-31 | Pfizer | Derivados de pirimidina condensados con un anillo heterociclico, composiciones que contienen los mismos, y uso de los mismos. |
FR2735777B1 (fr) * | 1995-06-21 | 1997-09-12 | Sanofi Sa | Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant |
WO1997020823A2 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | 2-amino quinazoline derivatives as npy receptor antagonists |
WO1997020822A1 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | Quinazolin-2,4-diazirines as npy receptor antagonist |
WO1997020821A1 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | Heteroaryl derivatives |
WO1997020820A1 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | Heteroaryl compounds |
DK0778277T3 (da) | 1995-12-08 | 2003-10-27 | Pfizer | Substituerede heterocycliske derivater som CRF antagonister |
EP0871442A1 (en) | 1996-01-09 | 1998-10-21 | Eli Lilly And Company | Benzimidzolyl neuropeptide y receptor antagonists |
CA2233307A1 (en) | 1996-02-07 | 1997-08-14 | Terence J. Moran | Thiophenopyrimidines |
US5688796A (en) | 1996-03-12 | 1997-11-18 | Eli Lilly And Company | Heterocyclic substituted benzothiophenes, compositions, and methods |
AU2042897A (en) | 1996-03-21 | 1997-10-10 | Banyu Pharmaceutical Co., Ltd. | Aminopyridine derivatives |
AU3176297A (en) | 1996-06-25 | 1998-01-14 | Novartis Ag | Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof |
KR20000029843A (ko) | 1996-08-06 | 2000-05-25 | 디. 제이. 우드;스피겔 알렌 제이 | 치환된피리도-또는피리미도-함유6,6-또는6,7-비시클릭유도체 |
JP2000516611A (ja) | 1996-08-14 | 2000-12-12 | ワーナー―ランバート・コンパニー | Mcp―1アンタゴニストとしての2―フェニルベンズイミダゾール誘導体 |
ATE384062T1 (de) | 1996-08-23 | 2008-02-15 | Novartis Pharma Gmbh | Substituierte pyrrolopyrimidine und verfahren zu ihrer herstellung |
TW477787B (en) | 1996-08-27 | 2002-03-01 | Pfizer | Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same |
CZ68199A3 (cs) | 1996-08-28 | 1999-11-17 | Pfizer Inc. | 6,5-Heterobicyklické deriváty, farmaceutická kompozice na jejich bázi a způsob léčení chorob |
AU6144098A (en) | 1997-02-14 | 1998-09-08 | Bayer Corporation | Amide derivatives as selective neuropeptide y receptor antagonists |
WO1998035944A1 (en) | 1997-02-14 | 1998-08-20 | Bayer Corporation | Amides as npy5 receptor antagonists |
JP3711238B2 (ja) | 1997-08-05 | 2005-11-02 | ファイザー・プロダクツ・インク | 神経ペプチドY受容体アンタゴニストとしての4−アミノピロ−ル(3,2−d)ピリミジン |
-
1999
- 1999-02-04 US US09/246,775 patent/US6187777B1/en not_active Expired - Fee Related
- 1999-02-05 PT PT99906756T patent/PT1054887E/pt unknown
- 1999-02-05 WO PCT/US1999/002500 patent/WO1999040091A1/en active IP Right Grant
- 1999-02-05 DE DE69930835T patent/DE69930835T2/de not_active Expired - Lifetime
- 1999-02-05 DK DK99906756T patent/DK1054887T3/da active
- 1999-02-05 AT AT99906756T patent/ATE323088T1/de not_active IP Right Cessation
- 1999-02-05 ES ES99906756T patent/ES2257851T3/es not_active Expired - Lifetime
- 1999-02-05 SI SI9930893T patent/SI1054887T1/sl unknown
- 1999-02-05 EP EP99906756A patent/EP1054887B1/en not_active Expired - Lifetime
- 1999-02-05 JP JP2000530520A patent/JP2003502272A/ja not_active Withdrawn
- 1999-02-05 AU AU26590/99A patent/AU747920B2/en not_active Ceased
- 1999-02-05 CA CA002319275A patent/CA2319275C/en not_active Expired - Fee Related
-
2000
- 2000-08-16 US US09/640,263 patent/US6583154B1/en not_active Expired - Fee Related
-
2006
- 2006-07-06 CY CY20061100932T patent/CY1105476T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
PT1054887E (pt) | 2006-06-30 |
AU747920B2 (en) | 2002-05-30 |
CY1105476T1 (el) | 2010-07-28 |
AU2659099A (en) | 1999-08-23 |
JP2003502272A (ja) | 2003-01-21 |
US6187777B1 (en) | 2001-02-13 |
CA2319275C (en) | 2007-10-16 |
DE69930835D1 (de) | 2006-05-24 |
EP1054887B1 (en) | 2006-04-12 |
DE69930835T2 (de) | 2006-10-19 |
US6583154B1 (en) | 2003-06-24 |
DK1054887T3 (da) | 2006-05-08 |
CA2319275A1 (en) | 1999-08-12 |
EP1054887A1 (en) | 2000-11-29 |
ES2257851T3 (es) | 2006-08-01 |
ATE323088T1 (de) | 2006-04-15 |
WO1999040091A1 (en) | 1999-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI1054887T1 (sl) | Biciklicni pridinski in primidinski derivati kot receptorski antagonisti nevropeptida y | |
ATE253039T1 (de) | Beta 2 -adrenergische rezeptor-agonisten | |
LT2001004A (en) | Fertilizer from sapropel and manufacture thereof | |
AP1869A (en) | b2- Adrenergic receptor agonists. | |
HK1083838A1 (en) | A2a adenosine receptor antagonists | |
BG105031A (en) | Heterocyclic inhibitors of p38 | |
AP2000001949A0 (en) | 4-Benzyl piperidine alkysulfoxide heterocycles and their use as subtype-selective NMDA receptor antagonists. | |
MXPA04000886A (es) | Derivados de triazolil-imidazopiridina y triazolilpurinas empledos como ligandos del receptor de adenosina a2a y su uso como medicamentos. | |
ATE347553T1 (de) | Amino-substituierte pyrazolo 1,5-aö-1,5- pyrimidine und pyrazolo 1,5-aö-1,3,5-triazine | |
MXPA03009644A (es) | Grupos azabiciclicos sustituidos para el tratamiento de enfermedades. | |
AU8377698A (en) | Inhibitors of p38 | |
MY117696A (en) | INHIBITORS OF p38 | |
AP2001002088A0 (en) | 4,4-Biarylpiperidine derivatives with opiod receptor activity. | |
WO1999029729A3 (en) | Antagonists of neuropilin receptor function and use thereof | |
SE9702773D0 (sv) | Novel compounds | |
DE60042066D1 (de) | Chimärische dr4 antikörper und ihre verwendung | |
MXPA03009185A (es) | Antagonistas de receptor a2a de adenosina combinados con compuestos de actividad neurotrofica en el tratamiento de la enfermedad de parkinson. | |
AU1783201A (en) | 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors | |
ATE281439T1 (de) | 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren | |
WO2003072572A8 (en) | Beta3-adrenergic receptor agonists | |
BG104022A (en) | New beta-amino and beta-azidocarboxylic acid derivatives, the production thereof and the use thereof as endothelin receptor antagonists | |
WO2001007431A3 (en) | Benzothiophene derivatives | |
PL375263A1 (en) | 2,5-substituted pyrimidine derivatives as ccr-3 receptor antagonists | |
TWI245756B (en) | Improved process for the preparation of 1,3-substituted indenes | |
BG106078A (en) | Thio-oxindole derivatives |